Provide feedbackProvide feedback
Home :: Infectious Disease

FDA committee recommends approval of OraSure's in-home HIV test

Wednesday, May 16 2012 | Comments
Evidence Grade 0 What's This?

The Food and Drug Administration's Blood Products Advisory Committee (BPAC) unanimously recommended approval of OraSure Technologies Inc.'s OraQuick in-home HIV test. Specifically, the committee voted 17-0 that the projected benefits of the test outweigh the potential risk of false positive and false negative test results. The committee also voted 17-0 that the available data provide reasonable assurance that the test is safe and effective for its intended use. The OraQuick in-home HIV...

The Food and Drug Administration's Blood Products Advisory Committee (BPAC) unanimously recommended approval of OraSure Technologies Inc.'s OraQuick in-home HIV test.

Specifically, the committee voted 17-0 that the projected benefits of the test outweigh the potential risk of false positive and false negative test results. The committee also voted 17-0 that the available data provide reasonable assurance that the test is safe and effective for its intended use.

The OraQuick in-home HIV test is an over-the-counter (OTC) version of the OraQuick Advance Rapid HIV-1/2 test that is used in professional settings. The OraQuick Advance test is the first and only FDA-approved and CLIA (Clinical Laboratory Improvements Amendments Act of 1988)-waived rapid point-of-care test that can detect antibodies to both HIV-1 and HIV-2 in oral fluid in 20 minutes, OraSure noted.

If approved, the test would be the first-ever OTC, completely in-home HIV test, Reuters reported. According to the news agency, OraSure expects the product to have a retail cost of less than $60 if it is approved and to be marketed in the next several months.

BPAC members urged OraSure to conduct postmarketing studies to ensure that the test is available to underserved populations, according to Reuters. The news agency added that some panel members also called for "strongly worded labeling" about the possibility of false results and procedures to help connect people who call a company hotline with questions to health care professionals.

Latest News

FDA to review Achillion's HCV drug on fast track basis Verusmed

Tuesday, May 15 2012 | Comments
Evidence Grade 0 What's This?

Achillion Pharmaceuticals Inc. received a fast track designation from the Food and Drug Administration for ACH-3102 for use as part of an interferon-free regimen for the treatment of chronic hepatitis C virus (HCV).

The drug, a pangenotypic second-generation nonstructural (NS) 5A inhibitor against HCV, is in Phase I testing. Achillion noted that ACH-3102 demonstrated...



Gilead's Quad combination HIV pill recommended for approval by FDA advisers Verusmed

Friday, May 11 2012 | Comments
Evidence Grade 0 What's This?

An advisory panel of the Food and Drug Administration voted in favor of approving Gilead Sciences Inc.'s once-daily combination tablet referred to as the Quad, which contains Gilead's Truvada (emtricitabine/tenofovir disoproxil fumarate) and the firm's investigational compounds elvitegravir and cobicistat, for the treatment of HIV-1 in treatment-naive...



FDA advisory committee recommends approval of Gilead's Truvada for HIV prevention Verusmed

Friday, May 11 2012 | Comments
Evidence Grade 0 What's This?

Gilead Sciences Inc.'s (emtricitabine/tenofovir disoproxil fumarate) should be approved to reduce the risk of HIV-1 among uninfected adults, according to a Food and Drug Administration advisory panel.

Gilead is proposing that Truvada be used in an HIV prevention strategy called pre-exposure prophylaxis (PrEP). If approved for PrEP, Truvada would be the first agent indicated for uninfected...



GlycoMimetics to develop AIDS vaccine with International AIDS Vaccine Initiative, Glycosensors and Diagnostics Verusmed

Thursday, May 10 2012 | Comments
Evidence Grade 0 What's This?

GlycoMimetics Inc. will collaborate with the International AIDS Vaccine Initiative (IAVI) and Glycosensors and Diagnostics LLC to develop an AIDS vaccine using glycomimetics, which are compounds that mimic...





  1. No articles have been read
  1. No articles have been emailed
Videos